瑞的Abrysvo疫苗在香港上市，成为了香港首个可用于保护孕妇的呼吸道合胞病毒（RSV）疫苗。 此前美国食品和药物管理局（FDA）批准了Abrysvo在32至36周怀孕的妇女中使用，该疫苗能够在新生儿出生的前六个月内提供保护。 呼吸道合胞病毒（Respiratory syncytial virus ...

With the season winding down, it’s time to have a look back not just at the last month, but at the 2024 year of Masters Tennis. Here is the monthly Masters tennis update by Abrysvo. The final ITF ...

For comparison, Pfizer reported yesterday that Abrysvo made full-year sales of $890 million, which - while respectable - were well below its competitor. However, it brought in $515 million in the ...

Abrysvo 是唯一获准用于 18-59 岁成年人的 RSV 疫苗。 辉瑞公司的呼吸道合胞病毒 (RSV) 疫苗Abrysvo已获得 FDA 批准，用于预防 18 至 59 岁患病风险较高的人群中与 RSV 相关的下呼吸道疾病。这种无佐剂的二价 RSV 预融合 F (RSVpreF) 疫苗是第一个也是唯一一个适用于 50 岁 ...

mResvia’s top-line score comes in slightly lower than Arexvy and slightly above Abrysvo, they note – notwithstanding differences in study design – and will be weighed up against the ...

The FDA has approved three vaccines to prevent RSV in adults who are 60 and older: Moderna’s mRESVIA, approved in June 2024, and GSK’s Arexvy and Pfizer’s Abrysvo, both approved in May 2023. The ...

Meanwhile, Brazil's National Health Surveillance Agency Anvisa has greenlighted the use of Pfizer's Abrysvo vaccine that prevents bronchiolitis in babies, which must be administered to mothers ...

GSK adds patent issued this week to infringement suit Abrysvo’s recent approval for ages 18-59 now in GSK crosshairs GSK Plc added allegations involving a newly issued patent to its 15-month-old ...